Substantially more critically ill patients with COVID-19 had antibodies to ADAMTS13 compared to non-COVID-19 ICU patients (55.9% vs. 5.6%, OR 21.53, 95% CI 4.609–98.15, p < 0.0001, Fig. 1D). The gene discussed is ADAMTS13; the disease is COVID-19.